羟苯磺酸钙口服制剂上市后安全性分析

doi:10.19803/j.1672-8629.20240539

摘要/Abstract

摘要： 目的分析羟苯磺酸钙口服制剂安全性信息,为临床合理用药提供参考。方法对 2004年1月1日至2023 年3月31日国家药品不良反应监测数据库中羟苯磺酸钙口服制剂的ADR发生特点及临床表现进行汇总;对2000年1月1日至2024年5月31日国内外文献数据库相关ADR报道进行整理;对国内外药品说明书进行分析。结果 2004年1月1日至2023年3月31日,共有羟苯磺酸钙制剂ADR病例报告 3 815例,其中严重病例182 例,严重病例报告中,皮肤损害报告较多;文献报道中毒性表皮坏死松解症较突出,且患者均伴随有肾功能损害。结论羟苯磺酸钙口服制剂可致严重皮肤损害,尤其肾功能损害需透析的患者需慎用,医疗机构应关注此风险。药品上市许可持有人应加强ADR监测,及时完善羟苯磺酸钙口服制剂说明书安全性信息。

关键词: 羟苯磺酸钙, 药品不良反应, 风险, 发热, 中毒性表皮坏死松解症, 监管措施, 说明书

Abstract: Objective To analyze the safety information of oral preparations of Calcium Dobesilate and provide reference for rational clinical drug use. Methods Individual cases of adverse drug reactions reported in China adverse drug reaction (ADR) database between January 1, 2004 and March 31, 2023, domestic and international literature published from January 1, 2000 to March 31, 2023, domestic and international drug specifications were analyzed. Results From January 1, 2004 to March 31, 2023, there were a total of 3 815 ADR reports of Calcium Dobesilate preparations in the database, involving 182 serious cases.in the reports of severe cases, skin damage was reported more frequently; Toxic epidermal necrolysis is more prominent in the literature, and the patients were accompanied by renal impairment. Conclusion Calcium Dobesilate oral preparation may cause serious skin damage, especially in patients with renal impairment requiring dialysis, and Medical institutions should pay attention to this risk. Marketing authorization holders should strengthen the monitoring of adverse reactions and update the information on safety in drug labels in time.

Key words: Calcium Dobesilate, Adverse Drug Reaction, Risk, Fever, Toxic Epidermal Necrolysis(TEN), Regulatory Measures, Instruction

中图分类号:

R972
R994.11

孟康康, 汤韧. 羟苯磺酸钙口服制剂上市后安全性分析[J]. 中国药物警戒, 2024, 21(11): 1288-1292.

MENG Kangkang, TANG Ren. Risks of Calcium Dobesilate Preparations to Safety[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1288-1292.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240539

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I11/1288

参考文献

[1] NMPA. Data Search[EB/OL].[2024-07-4]. https://www.nmpa.gov.cn/datasearch/search-result.html.
[2] HUANG QS, YANG J, CAO J, et al.Herpetic Epidermal Necrolytic-Relaxative Drug Rash Due to Calcium Dobesilate[J]. Journal of Clinical Dermatology(临床皮肤科杂志), 2013, 42(11): 2.
[3] LIU JJ, JIANG Y, LYU J, et al.A Case of Calcium Dobesilate-Induced Toxic Epidermal Necrolysis[J]. The Chinese Journal of Dermatovenereology(中国皮肤性病学杂志), 2015, 29(6): 2.
[4] GAO TT, QIN L, ZHOU XY.Toxic Epidermal Necrolysis Caused by Calcium Dobesilate Capsules: Report of 2 Cases[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2018, 20(3): 3.
[5] BAI H, WANG YF.A Case of Death Due to Drug Induced Hypersensitivity Syndrome Caused by Calcium Dobesilate[J]. Herald Of Medicine(医药导报), 2023, 42(2): 271-274.
[6] LI D, WU WF, WU HY.A Case of Exfoliative Dermatitis Caused by Calcium Dobesilate Capsule[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2022(10): 711-712.
[7] MIAO HX, TANG H, ZHAO QW, et al.Comparison of the Interference of Calcium Dobesilate on the Detection Results of Different Creatinine Enzymes[J]. Chinese Journal of Frontier health and Quarantine(中国国境卫生检疫杂志), 2023, 46(6): 559-562.
[8] HERVÉ ALLAIN, RAMELET AA, POLARD E, et al.Safety of Calcium Dobesilate in Chronic Venous Disease, Diabetic Retinopathy and Haemorrhoids[J]. Drug Safety, 2004, 27(9): 649-660.
[9] ScienceDirect. Calcium Dobesilate.[EB/OL].[2024-07-4] https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/dobesilate-calcium.
[10] NMPA. Announcement of the National Medical Products Administration on Revision of the Instructions for Calcium Dobesilate Oral Preparations (No. 37, 2024)[EB/OL]. (2022-04-07)[2024-07-10]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20240407151141153.html.
[11] HE SY, LI J.Research Advances of Calcium Dobesilate in the Treatment of Renal Fibrosis[J]. Journal of clinical Nephrology(临床肾脏病杂志), 2023, 23(9): 774-778.
[12] Retinopathy Group of the Diabetes Branch of the Chinese Medical Association (CMA). Expert Consensus on Prevention and Treatment of Diabetic Retinopathy[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2018, 10(4): 241-247.
[13] Diabetes and Microcirculation Specialized Committee of the Chinese Microcirculation Society. Expert Consensus on Clinical Use of Medications for Diabetic Microcirculatory Disorders (2021 Edition)[J]. Chinese Journal of the Frontiers of Medical Science(Electronic Version)(中国医学前沿杂志电子版), 2021, 13(4): 49-57.
[14] YU Y,HUANG ZY.Mechanism and Clinical Benefit of Calcium Dobesilate in Treatment of Diabetic Microvascular Complications[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2021, 40(12): 811-815.
[15] Panel of Experts of the Chinese Medical Association Nephrology Section. Chinese Guidelines for Clinical Diagnosis and Treatment of Diabetic Kidney Disease[J]. Chinese Journal of Nephrology(中华肾脏病杂志), 2021, 37(3): 255-304.
[16] Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert Consensus on the Diagnosis and Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2021, 54(5): 376-381.